Dupixent Sanofi-Aventis Australia Pty Ltd
Product name
Dupixent
Sponsor
Accepted date
Jun-2024
Active ingredients
dupilumab
Proposed indication
For the treatment of uncontrolled chronic obstructive pulmonary disease (COPD) associated with type 2 inflammation.
Application type
C (new indication)
Publication date
Jun-2024
Priority review
Involves faster TGA evaluation of vital and life-saving medicines for which a complete data dossier is available.